CompoAtlas

FOLIC ACID + VITAMIN C

Food supplement declared in France, declaration No 2022-2-950, decision dated 19 February 2022

FOLIC ACID + VITAMIN C (UPSPRING) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Borago officinalis 20 mg per day, β-Carotene, Folate (vitamin B9), Magnesium, Nicotinamide (vitamin B3). 1 point in its composition requires a check (prohibited substance, dose or novel food). 1 rule of use applies to its ingredients (limits and warnings).

Brand
UPSPRING
Food business operator placing the product on the market
RB NL BRANDS B.V.
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Tablet
Daily dose
1
Directions for use
1 Comprimé par jour
Intended populations
Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Taking anticoagulants, Taking diabetes medication
Objectives stated by the manufacturer (these are not authorised claims)
Pregnancy and breastfeeding

Declaration 323122, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Borago officinalis L.Graine (huile)Pression à froid20 mg

Other active ingredients

NamePer day
Huile de poissonnot declared
Acide lipoïquenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
beta-caroteneβ-Caroteneno limit (insufficient data)no fixed dose
pteroylmonoglutamic acidFolate (vitamin B9)1,000 µg200 µg
magnesium hydroxideMagnesium250 mg300 mg
nicotinamideNicotinamide (vitamin B3)900 mg54 mg
pyridoxine hydrochlorideVitamin B612 mg2 mg
L-ascorbic acidVitamin Cno limit (insufficient data)180 mg
cholecalciferolVitamin D100 µg (4,000 IU)5 µg (200 IU)
DL-alpha-tocopheryl acetateVitamin E300 mg30 mg

Additives

E460, E551, E470b

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Ne dépassez pas la dose journalière recommandée. Comme pour tous les compléments, consultez votre professionnel de santé avant touteutilisation.Si vous avez un problème de santé ou si vous prenez des médicaments (y compris des anticoagulants ou des hypoglycémiantsoraux), consultez un professionnel de santé avant de l'utiliser. En cas de grossesse, évitez de prendre d'autres compléments àforte teneur en vitamine A ou consultez votre médecin avant de prendre ce produit. Ce produit n'est pas destiné à être utilisé par des personnesâgées de moins de 18 ans. Conserver hors de la portée des jeunes enfants. Les compléments alimentaires sont destinés à compléter le régime alimentaire et ne doivent pas se substituer à un régime variée et équilibrée et à un mode de vie sain.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Borago officinalis L.
    Read the warning, when it applies and the studies cited
  • Huile de poisson
    Read the warning, when it applies and the studies cited

    FISH OIL

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Pain of rheumatoid arthritis.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Condition of application: Healthy mood balance.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression.

    Health Canada monograph dated 25 September 2026

  • Acide lipoïque
    Read the warning, when it applies and the studies cited

    DL-ALPHA-LIPOIC ACID/R-ALPHA-LIPOIC ACID

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Jacob et al. 1999, Konrad et al. 1999, Packer et al. 1995).

    Sources cited by Health Canada (3)
    • Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze GJ, Rett K. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radical Biology & Medicine 1999;27(3-4):309-314. PubMed Randomised trial
    • Konrad T, Vicini P, Kusterer K, Höflich A, Assadkhani A, Böhles HJ, Sewell A, Tritschler HJ, Cobelli C, Usadel KH. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999;22(2):280-287. PubMed
    • Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radical Biology & Medicine 1995;19(2):227-250. PubMed Review article

    Applies to products providing 42 milligrams or more DL-alpha-lipoic acid or 21 milligrams or more R-alpha-lipoic acid, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience sweating, paleness, chills, headache, dizziness and/or confusion (as these may be symptoms of serious low blood sugar) (Bae et al., 2013; Gullo et al., 2014; Bresciani et al., 2011; Chang et al., 2009).

    Sources cited by Health Canada (4)
    • Bae SM, Bae MN, Kim EY, Kim IK, Seo MW, Shin JK, Cho SR, Jeong GH. Recurrent Insulin Autoimmune Syndrome Caused by α-Lipoic Acid in Type 2 Diabetes. Endocrinol Metab (Seoul). 2013;28(4):326-330. PubMed
    • Bresciani E, Bussi A, Bazzigaluppi E, Balestrieri G. Insulin autoimmune syndrome induced by α-lipoic acid in a Caucasian woman: case report. Diabetes Care. 2011 Sep;34(9):e146. doi: 10.2337/dc11-0600. DOI
    • Chang HJ, Choi HS, Park MY, Leem SM, Jang YS, Park KS, Lee JM. A case of insulin autoimmune syndrome related to alpha-lipoic acid. Korean J Med 2009;76:600-604.
    • Gullo D, Evans JL, Sortino G, Ira D. Goldfine and Vigneri R. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking a-lipoic acid. Clinical Endocrinology 2014;81: 204-209. PubMed

    Health Canada monograph dated 27 June 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : UPSPRING

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “FOLIC ACID + VITAMIN C (UPSPRING): composition and regulation”, https://compoatlas.com/en/supplements/products/323122-folic-acid-vitamin-c, updated 15 November 2026.

List recorded in 2022. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line